Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
Not Applicable
Completed
- Conditions
- Meningitis, CryptococcalHIV Infections
- Registration Number
- NCT00002040
- Lead Sponsor
- Pfizer
- Brief Summary
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients. Both newly diagnosed and relapsed patients are eligible. The effectiveness of maintenance fluconazole therapy in sustaining a clinical cure in AIDS patients will also be evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Summitt Med Ctr / San Francisco Gen Hosp
🇺🇸Oakland, California, United States
Cook County Hosp
🇺🇸Chicago, Illinois, United States
SUNY / Health Sciences Ctr at Brooklyn
🇺🇸Brooklyn, New York, United States
Cornell Univ Med Ctr
🇺🇸New York, New York, United States
Buckley Braffman Stern Med Associates
🇺🇸Philadelphia, Pennsylvania, United States
Summitt Med Ctr / San Francisco Gen Hosp🇺🇸Oakland, California, United States